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Sex-specific eNOS activity and 
function in human endothelial cells
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Giulia Garrone4, Francesco Bifari  5 & Lucia Maria Vicentini1
Clinical and epidemiological data show that biological sex is one of the major determinants for 
the development and progression of cardiovascular disease (CVD). Impaired endothelial function, 
characterized by an imbalance in endothelial Nitric Oxide Synthase (eNOS) activity, precedes and 
accelerates the development of CVD. However, whether there is any sexual dimorphism in eNOS 
activity and function in endothelial cells (ECs) is still unknown. Here, by independently studying human 
male and female ECs, we found that female ECs expressed higher eNOS mRNA and protein levels both 
in vitro and ex vivo. The increased eNOS expression was associated to higher enzymatic activity and 
nitric oxide production. Pharmacological and genetic inhibition of eNOS affected migratory properties 
only in female ECs. In vitro angiogenesis experiments confirmed that sprouting mostly relied on eNOS-
dependent migration in female ECs. At variance, capillary outgrowth from male ECs was independent 
of eNOS activity but required cell proliferation. In this study, we found sex-specific differences in the EC 
expression, activity, and function of eNOS. This intrinsic sexual dimorphism of ECs should be further 
evaluated to achieve more effective and precise strategies for the prevention and therapy of diseases 
associated to an impaired endothelial function such as CVD and pathological angiogenesis.
There are substantial differences between men and women in cardiovascular disease (CVD) epidemiology, 
patho-physiology, clinical manifestations, effects of therapies, and outcomes1–3. However, the biological mecha-
nisms responsible for these sex differences are not yet fully understood. An impairment in endothelial function is 
associated to all the common cardiovascular risk factors and is a hallmark of CVD development and progression4, 5. 
Endothelial dysfunction is triggered by a reduced endothelial Nitric Oxide Synthase (eNOS) activity with a con-
sequent decrease in nitric oxide (NO) availability6, 7. Additional mechanisms of vascular NO formation via other 
NOS isoforms, such as the neuronal and inducible NOSs, may exist in blood vessels, and more generally in the 
CV system6. However, eNOS represents the main source of NO in endothelial cells (ECs) where it plays important 
roles in the control of several endothelial functions such as barrier integrity, vessel dilation, leukocyte adhesion, 
platelet aggregation, and angiogenesis7, 8. In ECs, eNOS is constitutively active under basal conditions and it can 
be further activated in response to shear stress, circulating hormones, and various autacoids7. Since females are 
more protected than males from CVD events until midlife, estrogens have long been assumed to mediate most 
of the observed sex-related differences1–3, 9, 10. Long term exposure to estrogens up regulates eNOS expression in 
ECs11, 12 whereas the activation of the enzyme and NO formation occur via rapid signaling pathways13, 14. Both 
the mechanisms participate in the improvement of EC function. As a result, flow mediated dilation (FMD), an 
indirect measure of NO-dependent endothelial function, is higher in women than in men until the early 50s15, 
and estrogen treatment improves FMD responses in recently postmenopausal women16, 17.
Recently, it has been demonstrated that more than 6.500 protein-coding genes are differentially expressed 
in men and women18. Regarding ECs, our and other groups have observed an intrinsic sexual dimorphism 
in some of their properties19, 20. Male and female ECs show sex-specific transcriptional profiles, with a higher 
expression of immune-related genes and a stronger response to shear stress in female compared to male ECs20. 
Knowledge of sex-specific expression patterns and of sexual dimorphisms in ECs may contribute to better under-
stand the well-known physio-pathological differences in male and female endothelial function. In this study, we 
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Figure 1. eNOS expression and activation are higher in F- than in M-ECs. (A) eNOS RNA was measured by RT-
qPCR and normalized to the housekeeping gene 18 S. ***p < 0.001, n = 3. (B) Total eNOS protein was evaluated by 
immunoblotting on male and female lysates. β-actin was used as a loading control. A representative blot (showing 
4 independent male and female lysates, 10 µg/lane) and the densitometric analysis of eNOS protein expression 
normalized to β-actin are shown. **p < 0.01; n = 14. (C) Upper panel, eNOS protein evaluated on lysates from twin 
male and female ECs at P1 passage (in vitro, left panel) or collected immediately after the flushing from cords (ex vivo, 
right panel). Representative blots out of two are shown. Lower panel, eNOS RNA measured by RT-qPCR on total 
RNA extracted from twin M- and F-ECs at P1 in vitro passage. Data are normalized to the housekeeping gene ACTB. 
*p < 0.05; n = 3. (D) eNOS dimers and monomers were separated by LT-PAGE as described in the Methods section. 
A representative blot and the densitometric analysis of the dimers-to-monomers ratio are shown. *p < 0.05; n = 6. 
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investigated eNOS expression both in vitro and ex vivo in human male and female ECs. Moreover, we studied the 
biological meaning of the observed sex-dimorphic eNOS expression by evaluating its involvement in relevant EC 
functions such as proliferation, migration, and in vitro angiogenesis.
Results
ENOS expression and activation are higher in female ECs. All cardiovascular risk factors are asso-
ciated with a loss in endothelial functions that is triggered by a decrease in NO production as consequence of a 
reduced eNOS activity6, 7. For that reason, we investigated eNOS availability in male and female human umbilical 
vein endothelial cells (HUVECs, abbreviated as M-ECs and F-ECs, respectively). We started our experiments by 
analyzing eNOS expression in in vitro cultured ECs. We found that both eNOS gene and protein expression were 
about 2-fold higher in F- than in M-ECs (Fig. 1A and B). Notably, the relative higher amount of eNOS was detected 
in F-ECs also when M- and F-ECs were derived from dizygotic male and female twin pairs (Fig. 1C, upper left panel 
for protein, and lower panel for mRNA), thus suggesting that sex-related differences in eNOS levels did not depend 
on the exposure to potentially diverse maternal environment. To exclude that the increase in eNOS expression was 
secondary to in vitro culturing, we collected and analyzed ECs from twin umbilical cords ex vivo. Consistent with 
in vitro culture data, an increase in female eNOS protein levels was detected in dizygotic male and female twin ECs 
immediately lysed after the flushing from cords, i.e. without any in vitro passage (Fig. 1C, upper right panel).
To explore the functional status of eNOS, we first investigated the dimer-to-monomer ratio in M- and F-ECs. 
Monomeric (130 kDa) and dimeric (260 kDa) forms of eNOS have been described in various tissues and cells, 
and the formation of dimers is critically required for the enzyme to functionally produce NO7, 21. We found a 
significant increase in the dimer-to-monomer ratio in F- compared to M-ECs (Fig. 1D), suggestive of a corre-
lation between the expression of eNOS and the amount of functional enzyme in F-ECs. Since a decrease in the 
dimer-to-monomer ratio may reflect eNOS uncoupling and production of reactive oxygen species (ROS)7, 21, we 
measured baseline ROS content in M- and F-ECs. However, we did not find any difference in ROS cell-associated 
levels between M- and F-ECs (Fig. S1), thus excluding that the lower dimer-to-monomer ratio in M-ECs may be 
due to a different oxidative behavior in comparison to F-ECs.
The phosphorylation of critical amino acids, such as Serine 1177 (Ser1177), contributes to the full activa-
tion of eNOS7, 21. Therefore, we analyzed baseline levels of phosphorylated eNOS (p-eNOSSer1177) by using 
phospho-specific antibodies in immunoblot analysis. Remarkably, the amount of p-eNOS was about 2-fold higher 
in F- in comparison to M-ECs (Fig. 1E), further confirming a straight correlation between the level of expression 
and the activation of the enzyme in F-ECs.
We further assessed whether the increase in eNOS activity resulted in higher NO production. The formation 
of NO occurs through two oxidation steps catalyzed by eNOS. Initially, N-hydroxy-L-arginine is formed from 
L-arginine, and this intermediate is next converted to NO with the formation of L-citrulline as the byproduct7, 21. 
Therefore, we quantified by liquid chromatography-mass spectrometric (LC-MS) analysis the citrulline-to-arginine 
ratio in M- and F-ECs. Importantly, the higher expression and activation of female eNOS were accompanied by a 
significant increase in the citrulline-to-arginine ratio (Fig. 1F), indicating higher NO production in F-ECs.
Finally, to exclude a role for other NOS isoforms in NO formation, we measured both inducible and neuronal 
NOS protein levels (iNOS and nNOS, respectively) in M- and F-EC lysates (Fig. S2). We could neither find iNOS 
nor nNOS expression in ECs from both sexes, thus excluding their involvement in the observed phenotype.
EC proliferation is eNOS-independent in both sexes. To find a biological significance for the increased 
female expression of eNOS, we compared proliferative properties of M- and F-ECs, and their dependence on 
eNOS activity by using L-NAME, a well-known functional NOS inhibitor. We did not observe any difference in 
growth rates of M- and F-ECs (Fig. 2A). Both M- and F-ECs showed comparable doubling times (47.5 ± 5.4 and 
47.6 ± 6.0 h for M- and F-ECs, respectively). Moreover, cell cycle distribution analysis showed a similar percent of 
cells in G1/S or G2/M phases (Fig. 2B). The addition of L-NAME (100 µM) did not modify cell growth at any time 
tested both in M- and in F-ECs (Fig. 2C).
Female ECs show higher eNOS-dependent migratory properties than male ECs. Having 
excluded the involvement of eNOS in proliferation, we analyzed its contribution to migration, another crucial 
property characterizing EC phenotype22. When EC motility was evaluated in a chemotaxis assay using FBS as 
attractant, F-ECs showed a greater migratory capability in comparison to M-ECs (Fig. 3A and B). The treatment 
with L-NAME (100 µM) completely abolished the higher F-EC migratory response bringing it to the same level 
of M-ECs (Fig. 3A). Although partially present also in M-ECs, the L-NAME-induced inhibition resulted signifi-
cantly higher in F-ECs (−32.6 ± 3.0% vs −15.7 ± 1.9% for F- and M-ECs, respectively) (Fig. 3B).
Since the establishment and maintenance of directional motility in chemotactic migration require lamellipo-
dia formation at the leading edge of migrating cells23–25, we compared lamellipodia extension between M- and 
F-ECs. Measurement of lamellipodial area revealed that F-ECs showed a significantly higher percent of the total 
cell area occupied by lamellipodia than M-ECs (Fig. 3C and D). No obvious differences were observed between 
cellular size (FSC-H) and complexity (SSC-H) (Fig. 3E), thus excluding broad differences between M- and F-EC 
morphology.
(E) A representative blot (showing 2 independent male and female lysates, 20 µg/lane) and the densitometric analysis 
of phospho-eNOSSer1177 (p-eNOS) protein expression normalized to β-actin are shown. *p < 0.05; n = 5. (F) LC-MS 
analysis was performed on M- and F-EC samples prepared and analyzed as described in the Methods section. Data 
are expressed as the citrulline-to-arginine ratio. *p < 0.05; n = 3.M- and F-ECs are green and red, respectively.
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Finally, we tracked random cell-motility of individual ECs by video imaging. This analysis revealed that, 
although M- and F-ECs showed a comparable cumulative distance (Fig. 3F), F-ECs displayed a greater directional 
persistence of movement than M-ECs (Fig. 3G and H).
NO is a short-lived molecule and therefore the cellular compartmentalization of eNOS is crucial to determine 
its distribution and biological effects7, 8. For this reason, we assessed the cellular localization of eNOS in M- and 
F-ECs. In agreement with functional and morphological results, we observed a more pronounced accumulation 
of the enzyme at the leading edge of polarized F-ECs (Fig. 3I). Collectively, all these results suggest that F-ECs 
possess higher migratory capabilities in comparison to M-ECs. These properties show a morphological relation-
ship with the presence of lamellipodia and a functional correlation with the activity and localization of eNOS.
2-D wound healing assay reveals eNOS-dependent migration in female ECs. Migration was 
also studied by using a 2-D wound healing test. In this assay, we did not observe any difference in the per-
centage of wound closure – measured 16 h after the scratch - between control M- and F-ECs (60.2 ± 3.0% and 
56.7 ± 4.1%, respectively) (Fig. 4A and B). To assess the role of eNOS-mediated migration in this assay, we added 
L-NAME (100 µM) to block the enzyme. We found that L-NAME was much more effective in inhibiting the 
percentage of wound closure in F- than in M-ECs. Indeed, the ability to close the wound was inhibited by 80% in 
L-NAME-treated F-ECs whereas it was reduced in a non significant manner in M-ECs (Fig. 4A and B). To test if 
the effect of L-NAME was attributable to its ability of specifically inhibiting eNOS activity, the expression of the 
Figure 2. EC proliferation is eNOS-independent in both sexes. (A) M- and F-ECs were cultured for the 
indicated times, and WST-8 absorbance was measured after 4 h of incubation. n = 3. (B) Cell cycle distribution 
was analyzed by FACS 48 h after plating. The percent of cells in each phase of the cycle is shown (solid, G0/G1; 
open, S; vertical, G2/M). n = 3–4 for M- and F-ECs, respectively. (C) M- and F-ECs were cultured in the absence 
(solid bars) or in the presence of L-NAME (100 µM, horizontal bars), and WST-8 was added for the last 4 h of 
incubation. Data are expressed as the percent of absorbance measured in the corresponding vehicle-treated 
cells. n = 3. M- and F-ECs are green and red, respectively.
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Figure 3. F-ECs show higher eNOS-dependent migratory properties than M-ECs: correlation with lamellipodia and 
eNOS localization. (A) Chemotaxis toward 10% FBS was performed in the absence (solid bars) or in the presence of 
L-NAME (100 µM, horizontal bars). Results are expressed as the number of migrating cells, and are the mean ± s.e.m 
of 25 counts from a representative experiment, repeated 3 times with similar results. ***p < 0.001 vs vehicle, &p < 0.05 
vs M-ECs. (B) Results are expressed as the percent of change in the number of migrating F-ECs over M-ECs in the 
presence of vehicle (**p < 0.01, n = 4) or L-NAME (**p < 0.01, n = 3). (C and D) Representative images of FITC-
labeled phalloidin-stained male (left panel) and female (right panel) showing lamellipodia (white arrows), and 
quantification of the area occupied by lamellipodia expressed as the percent of the total cell area. *p < 0.05, n = 3. 
Scale bar, 20 µm. (E) Forward scatter height (FSC-H) and side scatter height (SSC-H) of M- and F-ECs. n = 8 for 
M-ECs, and n = 9–10 for F-ECs. (F, G and H) Analysis of spontaneous cell-motility tracks by time-lapse imaging in 
M- and F-ECs, showing quantification of the cumulative distance, directionality, and migration distance. *p < 0.05, 
n = 108–178 for M- and F-ECs across 6 different experiments. (I) Representative pseudocolor lookup table (LUT) 
high-magnification confocal images of male and female ECs stained with anti eNOS highlighting the enzyme 
localization at the leading edge of migrating female ECs (white arrow). Scale bar, 20 µm.
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enzyme was silenced by using siRNA, and 48 h after transfection a scratch assay was performed. The knock-down 
of eNOS reduced the percentage of wound closure by about 50% in F-ECs whereas it did not significantly affect 
the capacity of M-ECs to close the wound (Fig. 4A and B). The ability of siRNA to efficiently silence eNOS expres-
sion in both M- and F-ECs is shown in Fig. S3.
Wound healing is the result of a complex process, which relies on both cell migration and proliferation. To 
extrapolate the contribution of cell growth to the closure of in vitro wounds, we performed the scratch assay 
on M- and F-ECs mitotically arrested by the addition of mitomycin (Mito-C, 500 ng/ml). Surprisingly, M-ECs 
became unable to close the wound when proliferation was blocked by mitomycin (Fig. 4A and B). On the other 
hand, inhibition of proliferation did not affect the ability of F-ECs to close the gap (Fig. 4A and B). Indeed, 
the percentage of wound closure was reduced by about 80% in mitomycin-treated M-ECs, while it remained 
unchanged in growth-arrested F-ECs (Fig. 4B). These results suggest that the ability to migrate and to close the 
wound significantly differs between M- and F-ECs. The activity of eNOS is a crucial requirement for F-EC migra-
tion and wound closure. At variance, M-EC wound closure is dependent on proliferation and is not significantly 
affected by eNOS inhibition.
eNOS is essential for in vitro angiogenesis of female ECs. Angiogenesis is the result of a coordinated 
process where the growth of new blood vessels relies not only on the migration of specialized cells at the forefront 
of vascular sprouts – the tip cells – but also on trailing cells that undergo proliferation to elongate the branch – 
the stalk cells26. Therefore, we set up a 3-D spheroid assay that recapitulates in vitro the angiogenic process27. In 
this assay, spheroids from M- or F-ECs undergo sprouting in a 3-D collagen matrix as the result of the migratory 
and proliferative contributions. Both spheroids from M- and F-ECs efficiently spread after 18 h of incubation 
(Fig. 5A), and no differences were observed in their overall total sprout length (1990 ± 315 and 1962 ± 275 µm for 
M- and F-ECs, respectively). To dissect eNOS-dependent migration and proliferation activities in EC sprouting, 
Figure 4. 2-D wound healing assay reveals eNOS-dependent migration in female ECs. (A) Representative 
photographs of male and female ECs taken at the time of wounding (t 0) and after a 16- h incubation in 20% 
FBS (vehicle) or in 20% FBS supplemented with L-NAME (100 µM) or mytomicin (MitoC, 500 ng/ml). Images 
of male and female ECs transfected with eNOS siRNA 48 h before wounding and then incubated for 16 h in 
20% FBS are also shown. Scale bar, 100 µm. (B) The percentage of wound closure at 16 h is shown. Vehicle, solid 
bars; L-NAME, horizontal bars; siRNA, squared bars; MitoC, vertical bars; L-NAME + MitoC, diagonal bars. 
**p < 0.01; ***p < 0.001 vs the corresponding vehicle, n = 3–4 for M- and F-ECs, respectively.
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Figure 5. eNOS is essential for in vitro angiogenesis in female ECs. (A) Representative images of spheroids 
from male or female ECs embedded in collagen gels in the absence (vehicle) or in the presence of L-NAME 
(1 mM) or MitoC (500 ng/ml). Also eNOS siRNA-transfected spheroids are shown. Photographs were taken 
18 h later. Scale bar, 100 µm. (B) Quantification of in vitro angiogenesis. Results are expressed as the percent 
of the total sprout length measured in vehicle–treated cells, set at 100%. Vehicle, solid bars; L-NAME, 
horizontal bars; siRNA, squared bars; MitoC, vertical bars; L-NAME + MitoC, diagonal bars. ***p < 0.001 
vs the corresponding vehicle, £p < 0.05 vs MitoC-treated F-ECs, n = 4–7 for M- and F-ECs, respectively. (C) 
Representative fluorescence photograph of a mosaic spheroid containing a 1:1 mixture of GFP-M-ECs and 
Cherry-F-ECs embedded in collagen gels. Photographs were taken 18 h later. Arrows indicate F-ECs located as 
tip cells. Scale bar, 100 µm. (D) Quantification of the percentage of tip cell contribution in sprouts containing 
both GFP-M-ECs and Cherry-F-ECs emerging from vehicle- or L-NAME-treated spheroids. *p < 0.05, n = 17.
www.nature.com/scientificreports/
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we either pharmacologically and genetically inhibited eNOS or mitotically arrested the cell cycle by the addition 
of mitomycin. When we added L-NAME (1 mM), we observed inhibition of sprouting only in F-EC spheroids 
(Fig. 5A and B). Quantification of the total sprout length showed a reduction of about 50% in F-ECs whereas 
M-ECs were totally unaffected (Fig. 5A and B). Comparable results were obtained when M- or F-ECs were 
silenced for eNOS gene expression (Fig. 5A and B). Addition of mitomycin (Mito-C, 500 ng/ml) impaired sprout-
ing in both M- and F-ECs (Fig. 5A and B). However, the inhibitory effect on sprouting was significantly higher in 
spheroids from growth-arrested M-ECs (about 70%) in comparison to spheroids from mitomycin-treated F-ECs 
(about 40%) (Fig. 5B). When we blocked both eNOS activity and proliferation, we observed a comparable inhibi-
tion of sprouting in M- and F-ECs (Fig. 5B). All together, these results suggest that F-ECs are crucially dependent 
on eNOS activity not only for their migratory phenotype but also for in vitro angiogenesis. At variance, M-ECs 
appeared to rely more on proliferation for both the events.
Our results obtained by studying migration and in vitro angiogenesis suggest that F-ECs possess a better 
migratory phenotype when compared to M-ECs. We therefore challenged the ability of M- and F-ECs to migrate 
during in vitro sprouting assay by performing experiments with mosaic spheroids prepared by mixing in a 1:1 
ratio GFP-carrying M-ECs and Cherry Red-expressing F-ECs (Fig. 5C). Quantification of the number of sprouts 
emerging from mixed spheroids showed that the majority of sprouts segregated only M- or F-ECs. However, in 
sprouts where ECs of both sexes were present, Cherry-F-ECs migrated more distally in about 73% of the sprouts 
(Fig. 5D). Notably, when mosaic spheroids were incubated in the presence of L-NAME (1 mM), the tip cell activ-
ity showed by F-ECs was significantly reduced to about 50% by the treatment (Fig. 5D). Again, our results confirm 
the hypothesis of a higher migratory phenotype shown by F-ECs and strictly controlled by eNOS activity.
Discussion
In this study, we show an intrinsically sexual dimorphism of the expression and activity of eNOS in human ECs. 
We have found that F-ECs possess a higher eNOS expression than M-ECs when analyzed ex vivo, i.e. before tissue 
culture, and that this difference is maintained in cell culture. Interestingly, the higher eNOS expression in F-ECs 
was confirmed when fraternal male and female twin pairs were analysed, thereby suggesting that the increased 
female eNOS expression is independent of the maternal environment.
Since sex hormones, especially estrogens, are well-known positive regulators of eNOS expression in ECs11, 12, 
it is possible to hypothesize that some differences in their fetal and/or maternal levels might be responsible for the 
increased eNOS expression in F-ECs. However, it has been shown that fetal cord blood contains steroids, includ-
ing 17β-estradiol, but their levels are comparable between male and female fetuses28, 29. Moreover, studies in twin 
pregnancies confirm that maternal serum steroid levels are unrelated to the fetal sex30. Therefore, the increased 
inborn female eNOS expression seems to be independent of estrogen exposure and concentrations. Whether 
other molecules of maternal and/or fetal origin might be responsible for the observed sexual dimorphism of 
eNOS expression is still unknown. Nevertheless, our data indicate that such sex-specific eNOS expression is 
maintained in vitro through sequential passages, thus suggesting a genetic/epigenetic regulation of this feature, 
and supporting the hypothesis that HUVECs have a sex.
It has been recently demonstrated that more than 6.500 protein-coding genes are differentially expressed in 
men and women18. Sexually dimorphic properties mainly result from differential expression of genes present in 
both sexes18, and it has been proposed that sex-specific biological features are the resultant of evolutionary pres-
sure31. Moreover, sex rather than cell type represents the main driver behind overall DNA methylation levels in 
pluripotent cell lines32. Interestingly, sex-differential expression of genes may be related to different disease sus-
ceptibility18. The higher expression of immune genes and the stronger capacity of inducing the differentiation of 
maternal regulatory T cells shown by female HUVECs compared to male HUVECs might be associated with the 
greater immune reactivity and predisposition for autoimmune responses observed in females in comparison to 
males20, 33. Our results suggest that eNOS, in addition to the well-known estrogen-dependent stimulation1–3, 9, 10, 
is constitutively expressed in an inborn sex-specific manner. The reduced incidence of CVD in premenopausal 
women relative to age-matched men has been largely attributed to the vascular protective effect of estrogens1–3, 34, 35, 
and their menopausal loss is accompanied by a progressive decline in endothelial function9, 10. How the 
estrogen-dependent component of the eNOS/NO production might interact in vivo with the innate, constitutive 
eNOS/NO component during lifetime, and whether this may contribute to the protection against CVD of pre-
menopausal female population, is however still unknown. Similarly, whether and through which mechanisms the 
expression of eNOS is lifelong regulated in male and female ECs need to be investigated.
Importantly, the increased eNOS expression observed in F-ECs corresponds to higher levels of activated 
enzyme. Furthermore, higher functional dimers and phosphorylated eNOS are associated to an increment in the 
citrulline-to-arginine ratio in F-ECs, thereby confirming a greater basal release of NO in F-ECs. A higher basal 
release of NO has been observed in aortic rings from endothelium of female rabbits compared to males36. A more 
robust endothelium-dependent vasodilation due to higher rates of NO release has also been described in premen-
opausal women compared to age-matched men37. Notably, our results demonstrate that, besides expression, also 
an increased eNOS activity and subsequent NO formation are constitutive properties of F-ECs.
eNOS is involved in several relevant EC functions including migration and angiogenesis7, 8, 22, 38. 
Pharmacological acute inhibition of eNOS activity with L-NAME impairs EC chemotaxis22, 39–41, and systemic 
administration of the drug blocks in vivo angiogenesis39, 40. Also the genetic loss of eNOS impairs in vivo Vascular 
Endothelial Growth Factor (VEGF)- or ischemia-induced angiogenesis42, 43. In accordance with the permissive 
role of eNOS on cell movement, our data show that the higher eNOS expression and activity were accompanied by 
an increased motility in F-ECs in comparison to M-ECs. Although eNOS appeared to be required for both M- and 
F-EC chemotaxis, pharmacological inhibition of the enzyme revealed a much higher dependence on eNOS for 
F-EC migration. Since NO is a short-lived molecule, the site of its production determines its biological effects7, 8. 
In mixed-sex EC cultures, the active form of eNOS specifically localizes to lamellipodia at the leading edge of 
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approximately half of the migrating cells44, 45, and polarization of eNOS and NO signalling (via generation of 
cGMP by NO-activated soluble guanylyl cyclase) have been demonstrated to define the direction of migration45. 
Consistently, our results show that F-ECs i) form lamellipodial projections over large areas; ii) have a higher eNOS 
concentration at the leading edge of polarized cells; iii) show a better directional motility than M-ECs.
The difference in eNOS dependence observed between M- and F-EC migration has been highlighted in the 
wound healing assay, where the spatial spreading of cells involves both motility and proliferation. Only F-ECs 
strictly required eNOS expression and activity for the closure of the wound. At variance, M-ECs spread in the 
wound region also when eNOS was inhibited or silenced but failed to close the gap when ECs were mitotically 
arrested.
A fine-tuned balance between cell growth and migration also underlies angiogenesis. Lamellipodia formation 
and motility of tip cells at the forefront of vascular sprouts are critical for vessel outgrowth and branching whereas 
elongation of the branch are sustained by proliferation of stalk cells26. Although we did not observe any sexual 
dimorphism in the overall sprouting ability of M- and F-ECs, we confirmed relevant sex-specific differences in 
eNOS dependence also in the in vitro angiogenic process. Again, only F-EC sprouting relied on eNOS expression 
and activity whereas capillary outgrowth was unaffected by eNOS inhibition in M-ECs. Vice versa, M-EC sprout-
ing was significantly inhibited when proliferation was blocked by mitomycin. Overall, our results demonstrate 
that M-ECs utilize eNOS-independent proliferation as the main mechanism for wound healing and sprouting. 
On the contrary, F-ECs were highly dependent on eNOS expression and activity for both the phenomena.
A major difference between M- and F-ECs is represented not only by the level of expression of eNOS but also 
by its localization. Lamellipodial eNOS is strictly required for EC motility and sprouting44, 45 and, in our experi-
ments, mainly migrating F-ECs showed eNOS localization at the leading edge. Indeed, the pool of eNOS achiev-
able for activation resides within the plasma membrane, and is enriched in specialized domains where several 
proteins can interact with eNOS to regulate its activity. Among these proteins, calcium-activated calmodulin and 
heat shock protein 90 (hps90) activate eNOS whereas caveolin-1 acts as a scaffold by inhibiting eNOS. An altered 
caveolin-1 membrane expression has been associated to a reduced eNOS level and activity in the plasma mem-
brane46. More recently, changes in the lipid component of EC membranes have been shown to affect the sub cel-
lular distribution of eNOS and its activation by different stimuli47. It is therefore possible to speculate that, besides 
eNOS, some differences in the expression and/or function of eNOS-interacting proteins, as well as in the lipid 
component of cell membranes, might also exist between M- and F-ECs leading to a different segregation of the 
enzyme among diverse cellular compartments. This hypothesis is currently under investigation in our laboratory.
In conclusion, our study shows for the first time a sexual dimorphism in the expression, activity, and func-
tion of eNOS in M- and F-ECs. Sex-differential expression of genes has been recently related to different disease 
susceptibility18. Nevertheless, biological sex is still under investigated in preclinical and in vitro studies, even 
when studies on sex-dependent pathologies are performed48–50. From this perspective, our results, providing new 
insights in sex-specific EC properties, may implement sex-related differences into health care strategies. A better 
understanding of EC dimorphisms and of their mechanisms may further suggest new targets for the design of 
more precise preventive and therapeutic strategies for diseases associated to an impaired endothelial function 
such as CVD and pathological angiogenesis.
Methods
Ethical approval. The procedure was carried out in accordance to local university guidelines and with the 
principles outlined in the Declaration of Helsinki. All experimental protocols were approved by the Ethics Board 
at the University of Milano (study 106/2011). Collection of cords was conducted by the clinicians of the Ospedale 
Macedonio Melloni, 20129 Milano, Italy, and anonymized samples were processed at the Dept of Medical 
Biotechnology and Translational Medicine, University of Milan, Milano, Italy. All pregnant women gave their 
written informed consent to study participation.
Cell cultures. HUVECs were freshly isolated from umbilical cords as described51, and used at passages 1–3. 
Cells were routinely grown in 199 medium supplemented with 20% fetal bovine serum (FBS), 25 µg/ml endothe-
lial cell growth supplement (ECGS), and 50 μg/ml heparin on 0.1% gelatine-coated surfaces. When HUVECs 
were immediately collected for ex vivo experiments, contaminating red blood cells were removed by red blood 
cell lysis buffer. Except twins, we used HUVECs pooled from two or more donors to minimize the variability 
associated with cells derived from a single male or female newborn donor.
Total RNA extraction for reverse transcription and quantitative real time PCR (RT-qPCR). Total 
RNA was extracted using the RNeasy® Mini Kit and accompanying QIAshredder™ (Qiagen). To avoid DNA con-
tamination of samples, a 15 min on-column incubation was carried out with DNase I (Qiagen). Reverse tran-
scription was performed using the SuperScript™ III First-Strand Synthesis System (Thermo Fisher Scientific). 
For the quantitative analysis of gene expression we used the ABI Prism® 7000 Sequence Detection System or the 
StepOnePlus® Real-Time PCR System (Thermo Fisher Scientific). Target sequences were amplified from 50 ng 
of cDNA using the TaqMan® Primer and Probe assays for human eNOS (NOS3, Hs00167166_m1) and for the 
endogenous control 18 S (Hs99999901_s1) (Thermo Fisher Scientific), or the PrimeTime® qPCR assays for eNOS 
(NOS3, Hs.PT.58523162) and actin (ACTB, Hs.PT.39a.22214847) (IDT). For calculation of results, the 2−ΔΔCt 
method was used.
Immunoblotting. Western blots for total and phospho-eNOS were carried out on total cell lysates prepared 
in Laemmli sample buffer containing 1 mM sodium orthovanadate. Equal amounts of proteins were separated 
by standard 8% SDS-PAGE. For the detection of eNOS dimers and monomers, HUVECs were lysed as previ-
ously described52, and the same amount of proteins (10 µg/lane) was subjected to low temperature 6% SDS-PAGE 
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(LT-PAGE, performed by keeping all gels and buffers at 4 °C during the whole procedure) under reducing con-
ditions (2.5% 2-mercaptoethanol)52. Proteins were then transferred onto nitrocellulose membranes following 
standard procedures. Membranes were blocked for 1 h with 5% non fat dried milk in Tris-buffered saline con-
taining 0.05% Tween-20 (TBS-T), and probed overnight at 4 °C with the following primary antibodies: anti-total 
eNOS, 1:2000 in 5% milk in TBS-T; anti-phospho eNOS (Ser1177) 1:1000 in 5% bovine serum albumin (BSA) 
in TBS-T; anti-β-actin, 1:1000 in 5% milk in TBS-T. After incubation with the appropriate HPR-conjugated sec-
ondary antibody (1:10.000 in 5% milk in TBS-T), immunoreactive bands were visualized by chemiluminescence 
(LiteAblot Turbo, EuroClone). Densitometric analyses of immunoblots were performed using the National 
Institute of Health (NIH) Image J software package. Full length blots are shown in Fig. 1.
Liquid chromatography-mass spectrometric (LC-MS) analysis. ECs cultured on 13-mm diameter 
glass coverslips were rapidly washed with a steam of water and immediately subjected to metabolic quenching 
as described in details in Martano et al.53, using u13C-Glucose as internal standard. Dry samples were recon-
stituted in 100 µl of 90% acetonitrile, 0.05% acetic acid and 0.025% trifluoroacetic acid, vortex for 30 seconds, 
and centrifuged at 3.500 g at 4 °C for 10 minutes. After a 2-min sonication, samples were centrifuged again, and 
supernatants were injected for analysis. Chromatographic separation was performed with Transcendent LX 
System (Thermofisher Scientific) using a Luna-Hilic column (particle size 3 µm, id 2.00 × 100 mm, Phenomex). 
Acquisition was performed with a triple quadrupole mass spectrometer TSQ-Quantiva (Thermofisher Scientific) 
coupled with electro-spray ionization source. Isocratic separation was performed as described54 by using 3% 
mobile phase A with MilliQ, 0.5% acetic acid, 0.025% trifluoroacetic acid, and 97% mobile phase B with ace-
tonitrile, 0.5% acetic acid, 0.025% trifluoroacetic acid. Injection was performed in full loop using 5 µl loop. MS 
parameter are: positive ion (V), 4.500; sheath gas, 45; aux gas, 15; sweep gas, 0; ion transfer tube temperature, 
275 °C; vaporizer temperature, 150 °C. Ions for selected reaction monitoring (SRM) are L-arginine: 116.20, 70.10, 
60.40; L-Citrulline: 159.05, 113.14, 70.10; u13C-Glucose: 169.08, 150.06.
Small interfering RNA (siRNA) transfection. To silence eNOS expression, HUVECs were transfected 
with validated StealthTM siRNA duplexes against human eNOS (GC content 48%, Thermo Fisher Scientific). A 
negative control duplex (Medium GC Duplex, 48% GC content, Thermo Fisher Scientific) was used as control. 
Both siRNAs were individually transfected at a 10 nM concentration using the PepMute transfection reagent 
according to the manufacturer’s instructions (SignaGen Laboratories). For scratch and sprouting assays, cells 
were transfected 48 h before wounding, and 24 h before plating to form spheroids, respectively. The knockdown 
of eNOS expression was analyzed by immunoblotting.
Proliferation assay. HUVECs were seeded in 96-well plates in triplicate at a density of 2 × 103 cells/well, and 
proliferation was measured by WST-8 assay according to the manufacturer’s instructions (Dojindo).
Flow cytometry analyses. For cell cycle analysis, HUVECs were re-suspended at a density of 1 × 106 cells/
ml in PBS containing 0.1% Nonidet, RNAase A (100 µl, stock 100 µg/ml), and propidium iodide (800 µl, stock 
50 µg/mL). After a 30-min incubation in the dark, cells were analyzed using a FACScalibur flow cytometer (BD 
Biosciences) operated by Cell Quest software. To study cell size and complexity, forward-scatter height (FSC-H) 
and side-scatter height (SSC-H) were acquired.
Motility assays. Cell migration was detected by chemotaxis experiments in Boyden chamber as previously 
described41. Briefly, HUVECs were suspended at a density of 1 × 106 cells/ml in 199 medium with 1% BSA and 
allowed to migrate toward 10% FBS as attractant. Polyvinylpyrrolidine (PVP)-free polycarbonate filters (8 μm 
pore size, Neuroprobe) were coated with type I collagen (10 µg/ml). After a 6-h incubation at 37 °C, the cells that 
had migrated to the lower side of the filter were stained with Diff-Quick stain, and 5 unit fields per filter were 
counted by a scorer blind to the experimental conditions using a Zeiss microscope.
For the wound healing assay, a scratch wound was applied on confluent HUVECs using a sterile pipette 
tip. HUVECs were then incubated in 199 medium with 20% FBS, and images were captured immediately after 
wounding (T0h) and 16 h later (T16h) at a 10x magnification with an Olympus U-CMAD3 phase contrast micro-
scope equipped with an Olympus digital camera. When indicated, cells were mitotically arrested with mitomy-
cin (500 ng/ml overnight). The percentage of wound closure (gap area at T0 minus gap area at T16h/gap area at 
T0 × 100) was measured with the NIH Image J software package.
Spontaneous motility was assessed on sparse HUVECs plated on glass bottom 6-well plates in 199 medium 
with 20% FBS. Images were acquired at intervals of 30 min overnight at 37 °C using a Evos FL Auto Cell Imaging 
System (objective ×10; Thermo Fisher Scientific). The motility of the cells was analyzed using the Tracking Tool 
PRO v2.0 Software (Gradientech AB) by tracking nucleus position over time and by superimposing migration 
origin at the zero-cross point55.
Immunofluorescence. For lamellipodia analysis, HUVECs were fixed in 4% paraformaldehyde 
(PFA)/0.12 M sucrose, and permeabilized with 0.3% Triton X-100. Fluorescein isothiocyanate (FITC)-labelled 
phalloidin was used to detect filamentous actin. For eNOS localization, HUVECs were fixed in −20 °C methanol 
for 2 min and then processed as previously described44, 56. Nuclei were stained with 4′,6-diamidino-2-phenylindole 
(DAPI). Images were obtained with a Zeiss LSM 510 Meta confocal microscope. The area occupied by lamellipo-
dia was quantified on fixed phalloidin-stained cells by using the NIH Image J program, and expressed as the 
percent of the total cell area.
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Lentiviral production and transduction. Lentiviral vectors expressing CherryRed or GFP were used. 
Production of lentiviruses was performed by plasmid transfection into HEK293T cells as previously described55. 
The titer of the lentiviral vector preparations was 1–4 × 109 transducing units/ml. Transduction with GFP or 
CherryRed was performed at a multiplicity of infection (MOI) of 10. HUVECs were transduced overnight in the 
presence of 0.5 μg/ml polybrene and re-fed with fresh medium the next day.
Three-dimensional (3-D) spheroid sprouting assay. HUVECs (1.000 cells/well in low-attachment 
96-well round bottom plates) were incubated overnight in the growth medium containing 20% methylcellulose 
to form spheroids. For mitotic inactivation, mitomycin (500 ng/ml) was added to this medium. Spheroids were 
then embedded into collagen gels as previously described57. Images were acquired with an Olympus U-CMAD3 
microscope equipped with an Olympus digital camera 18 h later. In-gel angiogenesis was quantified by measuring 
the cumulative length of all of the capillary sprouts originating from individual spheroids using the NIH Image 
J program. At least, 10 randomly selected spheroids per experimental group were measured in each experiment. 
To obtain mosaic spheroids, male and female HUVECs transduced with GFP or Cherry Red were mixed at a 1:1 
ratio. Images were acquired 18 h later using a Zeiss LSM 510 Meta confocal microscope.
Reagents and Antibodies. All tissue culture reagents were from Euroclone SpA except ECGS and hep-
arin (Sigma Aldrich, cat #E2759 and #H3149, respectively). NG-Nitro-L-arginine methyl ester (L-NAME, cat 
#N5751), methylcellulose (cat #M0512), FITC-labelled phalloidin (cat #P5282), and DAPI (cat #D9542) were 
from Sigma Aldrich; collagenase (cat #17454) and rat tail collagen I (cat #47254) from Serva; recombinant 
human VEGF165 (cat #100) from Peprotech; mitomycin (cat #BIA-M1183) from Tebu-bio. Primary antibodies 
used were: mouse monoclonals anti-eNOS (BD Transduction Laboratories, cat #610296) and anti-β-actin (Sigma 
Chemicals, cat #A2228), and rabbit polyclonal anti phospho-eNOS (Ser1177) (Cell Signalling Technology, cat 
#9571). HRP-conjugated secondary antibodies were from Dako (cat #P0260 and #P0399 for rabbit anti-mouse 
and swine anti-rabbit antibodies, respectively). A goat anti-mouse CY3 (cat #29-0382-75, GE Healthcare) was 
used in immunofluorescence experiments to detect eNOS.
Statistical procedures. Unless otherwise indicated, data are the mean ± s.e.m of at least 3 independent 
experiments. Statistical significance was determined by unpaired Student’s t-test or one-way analysis of variance 
(ANOVA) followed by Bonferroni’s multiple comparison test using the GraphPad Prism version 5.00 software.
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